X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/kyowa-kirin-announces-acceptance-of-abstract-for-presentation-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting-2024-302106101.html
https://www.prnewswire.com/news-releases/kyowa-kirin-announces-first-patient-enrolled-in-the-phase-2-clinical-trial-evaluating-tivozanib-eye-drops-in-patients-with-diabetic-macular-edema-302054044.html
https://www.prnewswire.com/news-releases/aveo-oncology-announces-completion-of-enrollment-in-pivotal-phase-3-tinivo-2-study-of-fotivda-tivozanib-in-combination-with-opdivo-nivolumab-in-advanced-renal-cell-carcinoma-301864465.html
https://www.globenewswire.com/news-release/2022/10/12/2533371/0/en/U-S-Patent-Trademark-Office-Allows-AVEO-Oncology-s-Patent-Application-Covering-Use-of-FOTIVDA-for-the-Treatment-of-Refractory-Advanced-Renal-Cell-Carcinoma.html
https://www.globenewswire.com/news-release/2022/06/06/2456662/0/en/AVEO-Oncology-Presents-Three-Posters-for-Tivozanib-at-the-2022-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2022/02/14/2384775/0/en/AVEO-Oncology-to-Present-Positive-New-Long-Term-PFS-Data-from-Phase-3-TIVO-3-Study-of-FOTIVDA-tivozanib-in-Third-and-Fourth-Line-Renal-Cell-Carcinoma.html
https://www.globenewswire.com/news-release/2022/01/20/2370094/0/en/AVEO-Oncology-Presents-Three-Posters-for-Tivozanib-Immunotherapy-Combinations-at-the-2022-ASCO-GI-Cancers-Symposium.html
http://investor.aveooncology.com/news-releases/news-release-details/aveo-oncology-announces-addition-fotivdar-tivozanib-national
https://www.businesswire.com/news/home/20210310005893/en/AVEO-Oncology-Announces-U.S.-FDA-Approval-of-FOTIVDA%C2%AE-tivozanib-for-the-Treatment-of-Adult-Patients-with-Relapsed-or-Refractory-Advanced-Renal-Cell-Carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma
https://www.fiercepharma.com/pharma/aveo-s-tivozanib-now-approved-as-fotivda-will-hit-market-after-years-setbacks
http://www.pharmafile.com/news/573090/fda-approves-aveo-s-kidney-cancer-treatment
https://www.businesswire.com/news/home/20210211005220/en/AVEO-Oncology-Announces-Presentation-of-Key-Subgroup-and-Quality-of-Life-Analyses-from-the-Phase-3-TIVO-3-Study-of-Tivozanib-in-Renal-Cell-Carcinoma
https://www.businesswire.com/news/home/20210115005128/en/AVEO-Oncology-Announces-Results-from-Phase-1b-Portion-of-DEDUCTIVE-Study-of-Tivozanib-FOTIVDA%C2%AE-in-Combination-with-IMFINZI%C2%AE-durvalumab-in-Previously-Untreated-Metastatic-Hepatocellular-Carcinoma
https://www.businesswire.com/news/home/20200915006253/en/AVEO-Oncology-Announces-European-Urology-Publication-of-Final-Overall-Survival-Data-from-Phase-3-TIVO-3-Study-of-Tivozanib-in-Renal-Cell-Carcinoma
https://www.businesswire.com/news/home/20200212005900/en/AVEO-Oncology-Announces-Publication-Phase-1b2-Study
https://www.fiercebiotech.com/research/could-anti-cancer-gene-p53-be-a-target-treating-kidney-cancer
https://www.biospace.com/article/releases/aveo-announces-presentation-of-updated-os-and-subgroup-data-from-phase-3-tivo-3-trial-of-tivozanib-in-renal-cell-carcinoma-/?s=95
https://www.fiercebiotech.com/biotech/fda-tells-aveo-no-again-for-tivozanib-as-biotech-tries-to-find-yet-another-path-forward
https://www.businesswire.com/news/home/20191104005273/en/AVEO-Oncology-Announces-Regulatory-Update-Tivozanib-Renal/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.biospace.com/article/with-additional-os-data-in-hand-aveo-oncology-eyes-nda-for-rcc-drug-tivozanib/?s=95
https://www.biospectrumasia.com/news/25/14128/kyowa-kirin-buys-back-tivozanib-rights-from-aveo-oncology.html
https://endpts.com/fda-stiff-arms-aveo-on-tivo-again-sunovion-parkinsons-drug-rejected/
http://www.pharmatimes.com/news/astrazeneca,_aveo_oncology_form_lung_cancer_collaboration_1272675
https://www.fiercepharma.com/pharma/former-aveo-cfo-johnston-found-guilty-misleading-investors-about-prospects-for-cancer-drug
https://www.prnewswire.com/news-releases/eusa-pharma-announces-sale-of-critical-care-business-to-serb-pharmaceuticals-853156511.html
http://www.pharmatimes.com/news/three_cancer_treatments_approved_for_use_on_nhs_scotland_1243739
Market Place
Share 
